By Charles Alovisetti
Apr 16, 2025
Trump’s return to the White House brings renewed uncertainty for cannabis and hemp policy. This blog breaks down his appointees’ stances, key campaign statements, and what the industry can expect in the months ahead.
By Steve Pemberton
Apr 15, 2025
Nebraska’s Attorney General has issued cease-and-desist letters to over 100 hemp retailers, citing illegal Delta-9 THC levels. The crackdown highlights the state’s aggressive stance on synthetic THC and mirrors growing national pressure on hemp businesses. Find out how these enforcement actions could impact the industry and what steps businesses can take to stay compliant.
By Genevieve Meehan, Barine Majewska
Apr 9, 2025
New Mexico becomes the third state in the U.S. to legalize the supervised medical use of psilocybin with the passage of Senate Bill 219, the Medical Psilocybin Act. Notably, the bill was mandated by New Mexico’s legislature, and not by voter ballot measure as in Colorado and Oregon.
By Charles Alovisetti
Mar 27, 2025
The Corporate Transparency Act (CTA) has undergone significant changes with the issuance of a new Interim Final Rule (IFR) by the Financial Crimes Enforcement Network (FinCEN). These changes significantly reduced the law's scope, exempting most U.S. companies from Beneficial Ownership Information (BOI) reporting requirements. In this Insights post, we break down the key takeaways of the IFR and explain their impact on your business.
By Juliana Todeschi
Mar 24, 2025
Florida’s Rule 5K-4.034 establishes new regulations for hemp extract products, focusing on ingredient restrictions and child-resistant packaging. The rule bans 66 additives, including certain FDA-approved colorants, and adopts ASTM standards for child-resistant packaging to reduce product appeal to minors. While enforcement of the rule begins in June 2025, FDACS is already enforcing existing statutes and regulations, making early compliance essential for businesses operating in the state.
Commentary and analysis on cannabis, hemp, psychedelics, and other emerging therapies from the attorneys and policy specialists at the nation’s leading cannabis law firm.